Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Lippman

Showing results (61-70 of 340) with videos related to

Pageof 34
Sort By:
Cancer Treatment Reviews|March 24, 2024
If it's a target, it's a pan-cancer target: Tissue is not the issueJacob J Adashek, Shumei Kato, Jason K Sicklick, et al.
Nature Cancer|December 15, 2023
Considering molecular alterations as pan-cancer tissue-agnostic targetsJacob J Adashek, Shumei Kato, Jason K Sicklick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2005
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemopreventionAndrew J Dannenberg, Scott M Lippman, Jason R Mann, et al.
European Urology|December 4, 2003
Prevention of prostate cancer with finasteride: US/European perspectiveIan M Thompson, Eric A Klein, Scott M Lippman, et al.
Carcinogenesis|April 19, 2014
Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology studyYonggang He, Yilei Gong, Jian Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomesYair Lotan, Jeffrey A Cadeddu, J Jack Lee, et al.
Cancer Research|July 20, 2006
RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoAZheng D Liang, Scott M Lippman, Tsung-Teh Wu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 10, 2006
The cost of prostate cancer chemoprevention: a decision analysis modelRobert S Svatek, J Jack Lee, Claus G Roehrborn, et al.
Cancer Immunology Research|August 14, 2019
Microsatellite-Stable Tumors with High Mutational Burden Benefit from ImmunotherapyAaron M Goodman, Ethan S Sokol, Garrett M Frampton, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 12, 2018
Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancerDuc Ha, Andrew L Ries, Peter J Mazzone, et al.
Pageof 34

Showing results (61-70 of 340) with videos related to

Sort By:
Pageof 34
Cancer Treatment Reviews|March 24, 2024
If it's a target, it's a pan-cancer target: Tissue is not the issueJacob J Adashek, Shumei Kato, Jason K Sicklick, et al.
Nature Cancer|December 15, 2023
Considering molecular alterations as pan-cancer tissue-agnostic targetsJacob J Adashek, Shumei Kato, Jason K Sicklick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2005
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemopreventionAndrew J Dannenberg, Scott M Lippman, Jason R Mann, et al.
European Urology|December 4, 2003
Prevention of prostate cancer with finasteride: US/European perspectiveIan M Thompson, Eric A Klein, Scott M Lippman, et al.
Carcinogenesis|April 19, 2014
Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology studyYonggang He, Yilei Gong, Jian Gu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomesYair Lotan, Jeffrey A Cadeddu, J Jack Lee, et al.
Cancer Research|July 20, 2006
RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoAZheng D Liang, Scott M Lippman, Tsung-Teh Wu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 10, 2006
The cost of prostate cancer chemoprevention: a decision analysis modelRobert S Svatek, J Jack Lee, Claus G Roehrborn, et al.
Cancer Immunology Research|August 14, 2019
Microsatellite-Stable Tumors with High Mutational Burden Benefit from ImmunotherapyAaron M Goodman, Ethan S Sokol, Garrett M Frampton, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 12, 2018
Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancerDuc Ha, Andrew L Ries, Peter J Mazzone, et al.
Pageof 34